Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in Pediatric Subjects With Biliary Atresia
NCT06121375Phase 3Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 10
01
Overview
A Phase 3 trial of obeticholic acid in biliary atresia, sponsored by Intercept Pharmaceuticals. Started Sep 2024; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT06121375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06121375.